Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue - Concepedia

Concepedia

Publication | Open Access

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

DOI Full Paper Access

295

Citations

31

References

2009

Year

Johan Jendle, Michael A. Nauck, David R. Matthews, Anders Frid, Kjeld Hermansen, Maria Düring, Marija Zdravković, Boyd J. Strauss, A. J. Garber

Diabetes Obesity and Metabolism

Abstract

Liraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D.

References

	Year	Citations

Page 1